Contrave Shortage: What Providers and Prescribers Need to Know in 2026

Contrave Availability in 2026: A Provider Briefing

Patients are increasingly asking about weight-management medications, and Contrave (Naltrexone 8 mg / Bupropion 90 mg extended-release) remains one of the few FDA-approved oral options. But providers are hearing a common complaint from patients: "My pharmacy says they don't have it."

This briefing covers the current supply situation, prescribing implications, cost and access challenges, and tools you can use to help your patients get their Contrave prescriptions filled.

Current Supply Status

As of early 2026, Contrave is not listed on the FDA Drug Shortage Database. The manufacturer, Currax Pharmaceuticals, has not reported supply disruptions, and the medication is available through standard pharmaceutical distribution channels.

However, de facto availability at the pharmacy level is inconsistent. This is not a manufacturing shortage — it's a distribution and demand mismatch driven by several market factors.

Timeline: How We Got Here

Understanding the context helps frame the current situation:

• September 2014: FDA approves Contrave (NDA 200063) for chronic weight management
• 2014–2020: Moderate adoption; Orexigen Therapeutics markets the drug, later acquired by Nalpropion Pharmaceuticals, then Currax Pharmaceuticals
• 2021–2023: The GLP-1 era begins — Wegovy (semaglutide) and later Zepbound (tirzepatide) generate massive demand for weight-loss medications
• 2024–2025: Widespread GLP-1 shortages push some patients and providers toward oral alternatives, increasing interest in Contrave
• 2026: Contrave remains brand-name only, with no FDA-approved generic. Individual pharmacy stocking varies widely

Prescribing Implications

When prescribing Contrave, providers should be aware of factors that may affect patients' ability to fill their prescriptions:

Pharmacy Stocking Variability

Many chain pharmacies use demand-based automated ordering systems. If a location fills few Contrave prescriptions per month, the system may not maintain stock. This doesn't mean the medication is unavailable — it means the patient may need to:

• Request a special order (typically 1–2 business days)
• Transfer the prescription to a pharmacy with existing stock
• Use a mail-order option

Prior Authorization Requirements

Approximately 30–40% of commercial insurance plans cover Contrave, but most require prior authorization. Common criteria include:

• Documented BMI ≥30 kg/m² (or ≥27 with comorbidity)
• Evidence of failed diet and exercise intervention
• Sometimes step therapy with other agents first

Proactively submitting prior authorization documentation when prescribing can reduce fill delays.

Medicare and Medicaid Considerations

Medicare Part D generally does not cover anti-obesity medications, including Contrave. This is a significant barrier for patients 65 and older. Some Medicaid plans provide coverage with prior authorization, but this varies by state.

The Availability Picture

Contrave's availability challenges stem from a combination of factors:

• Single manufacturer: Currax Pharmaceuticals is the sole producer, with no generic competition
• High acquisition cost: Wholesale cost makes pharmacies cautious about stocking without confirmed demand
• Insurance gaps: Limited coverage means fewer filled prescriptions, creating a negative feedback loop for pharmacy stocking
• Market competition: GLP-1 agonists have captured significant market attention and formulary priority

Despite these challenges, Contrave is available — it just requires more effort from patients and providers to locate and access it.

Cost and Access Landscape

Understanding the financial barriers your patients face can help guide conversations:

• Retail cash price: $700–$900/month (120 tablets)
• With commercial insurance: Copays $100–$600/month (when covered)
• CurAccess Program: $99/month or less with free shipping (manufacturer program)
• Copay savings card: For commercially insured patients, covers copay amounts over $99 (up to $446.40 per fill)
• Discount cards (GoodRx, SingleCare): $610–$660 at participating pharmacies

The CurAccess Program through Currax Pharmaceuticals is often the most cost-effective option for patients. Details are available at contrave.com/save.

Tools and Resources for Providers

Several tools can help you support patients who are prescribed Contrave:

Medfinder for Providers

Medfinder allows providers and staff to check real-time pharmacy stock for Contrave. This can be integrated into your workflow when prescribing — identify a pharmacy with stock before sending the prescription, reducing patient frustration.

CurAccess Provider Resources

Currax Pharmaceuticals offers provider-facing resources at contravehcp.com, including dosing guides, patient education materials, and savings program enrollment support.

Prior Authorization Support

Consider developing standardized prior authorization templates for weight-management medications. Key documentation to include:

• Current BMI and weight history
• Weight-related comorbidities
• Previous diet/exercise interventions and outcomes
• Clinical rationale for Contrave specifically (e.g., oral preferred, not a controlled substance, dual-mechanism approach)

Alternative Prescribing Options

If Contrave is inaccessible for a patient, other FDA-approved anti-obesity medications include:

• Qsymia (Phentermine/Topiramate ER) — oral, Schedule IV, ~$200–$250/month
• Orlistat (Xenical 120 mg / Alli 60 mg OTC) — lipase inhibitor, $40–$300/month
• Saxenda (Liraglutide 3 mg) — daily injectable GLP-1, $1,000–$1,400/month
• Wegovy (Semaglutide 2.4 mg) — weekly injectable GLP-1, $1,300–$1,600/month
• Zepbound (Tirzepatide) — weekly injectable dual GIP/GLP-1

For a patient-facing comparison, see our article on alternatives to Contrave.

Looking Ahead

Several trends will shape Contrave access going forward:

• Generic timeline: While no generic is currently approved, patent challenges may open the door for generic Naltrexone/Bupropion ER in the coming years. This would significantly improve affordability and pharmacy stocking.
• Insurance expansion: As anti-obesity medication coverage gains policy momentum — particularly after the Treat and Reduce Obesity Act discussions — more plans may add Contrave to their formularies.
• Telehealth growth: Telehealth platforms are increasingly prescribing weight-management medications, including Contrave. This expands access but also increases demand.
• Off-label compounding: Some telehealth companies offer separately prescribed generic Naltrexone + Bupropion. While more affordable ($30–$80/month), this is not the FDA-approved combination product. Providers should be aware of the clinical differences.

Final Thoughts

Contrave remains a valuable tool in the anti-obesity medication portfolio — it's the only FDA-approved oral combination that targets both appetite and cravings without being a controlled substance. The access challenges are real but manageable with proactive prescribing practices, patient education about savings programs, and tools like Medfinder.

For a practical guide on supporting patients through the fill process, see our companion article: How to help your patients find Contrave in stock.

For cost-saving strategies you can share with patients, see: How to save money on Contrave in 2026.